Glenmark gets US approval for lithium carbonate

Glenmark Generics (GGI), the US subsidiary of Glenmark Generics, has received marketing approval from the United States Food and Drug Administration (USFDA) for selling its cheap versions of lithium carbonate capsules.

The approvals are for 150 mg, 300 mg and 600 mg capsules of the drug, used in the treatment of patients suffering from manic disorders associated with bi-polar disease. Typical symptoms of manic disorders include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, elation, poor judgment, aggressiveness, and possibly hostility.

According to IMS Health, Lithium Carbonate capsules had annual sales of $10 million for the period ending September 2008. 

 

A press release said Glenmark would immediately commence marketing and distribution of these products in the US market.

Currently Glenmark sells 38 generic products in the US market, besides another 40 abbreviated new drug applications (ANDAs) filed with the U.S. FDA pending approval.